Modus Therapeutics' Clinical Progress with Sevuparin
Karolinska Development AB has exciting news regarding its portfolio company Modus Therapeutics as they successfully wrap up patient enrollment for part 1 of their phase 2a study focusing on sevuparin. This promising treatment is aimed at patients suffering from chronic kidney disease, particularly those experiencing anemia.
The Study's Objectives and Design
This important phase 2a study is structured to assess both the safety and appropriate dosing levels of sevuparin in patients with chronic kidney disease, which typically affects older populations and can lead to various complications. The research is being carried out at two renowned nephrology centers in Italy and involves healthy volunteers alongside those diagnosed with the condition. By accurately examining sevuparin's effects, this study will lay the groundwork for future evaluations, including a proof-of-concept phase that examines the drug's efficacy with repeated doses.
Significance of the Milestone
The completion of patient enrollment marks a significant accomplishment for Modus Therapeutics. As Viktor Drvota, the CEO of Karolinska Development, stated, this milestone not only showcases the company’s commitment and progress but also sets a clear path for future advancements in the drug's potential. Successfully moving into the next critical phase reflects the essential developmental steps Modus Therapeutics must take to bring this treatment to life.
Ownership and Support
Karolinska Development retains a substantial share in Modus Therapeutics, holding a 66 percent stake. This robust ownership reflects their belief in the potential success of the company and their commitment to advancing treatments that could help change lives. They are dedicated to supporting Modus Therapeutics as they embark on the next phase, which represents a vital growth and validation opportunity.
Contacting Karolinska Development
If you seek further details regarding this project or have inquiries about the company, you can reach out to Viktor Drvota directly at the provided contact information. Communication is key in keeping all stakeholders informed about the company's developments and progress.
Karolinska Development's Vision
Karolinska Development AB is recognized as a premier Nordic life sciences investment company. They focus intently on discovering and nurturing groundbreaking medical innovations originating from the Nordic region, collaborating closely with talented entrepreneurs and leadership teams. The company is committed to translating these innovations into commercial products aimed at enhancing patient care while also providing solid investment returns.
Engaging with world-class medical innovations from prestigious institutions such as the Karolinska Institutet, Karolinska Development strives to form partnerships that ensure a successful transition from scientific ideas to viable therapeutic solutions. With a portfolio of eleven companies targeting innovative treatments for serious diseases, they are quickly becoming a leader in the life sciences investment sector.
Frequently Asked Questions
What is the focus of Modus Therapeutics' phase 2a study?
The study focuses on evaluating the safety and efficacy of sevuparin in patients with chronic kidney disease and anemia.
Where is the study being conducted?
The clinical study is conducted across two nephrology centers in Italy.
How much ownership does Karolinska Development hold in Modus Therapeutics?
Karolinska Development holds a 66 percent stake in Modus Therapeutics.
What are the next steps after this phase of the study?
Following this phase, Modus Therapeutics will move into a proof-of-concept study to further evaluate sevuparin's therapeutic potential.
Who can I contact for more information about this initiative?
You can contact Viktor Drvota, CEO of Karolinska Development, via the provided contact details for inquiries regarding this project.
